Clinical use of intravenous iron: administration, efficacy, and safety.
This section reviews the history, pharmacology, administration, efficacy, and toxicity of intravenous iron. Intravenous iron offers advantages over oral iron for the treatment of iron deficiency anemia across a wide range of disease states associated with absolute and functional iron deficiency. However, there remain concerns about the acute safety profiles of the available preparations and the potential for long-term toxicity with their repeated administration. Seven intravenous iron formulations are available. Confusion concerning the relative toxicities of the different formulations abounds. The similarities and differences are discussed. Iron repletion has been associated with adverse outcomes in infections. The relationship, if any, between intravenous iron administration and infections is reviewed. The potential advantages of total dose infusion (TDI), complete repletion in a single setting, are highlighted. A new paradigm for iron replacement therapy in iron deficiency anemia is presented.
Georgetown University School of Medicine, Washington, DC, USA. mauerbachmd@aol.com
Michael
M
Auerbach
Harold
H
Ballard
D005290:Ferric Compounds / Q000627:therapeutic use; D052203:Ferrosoferric Oxide; D006801:Humans; D007275:Injections, Intravenous; D007501:Iron / Q000008:administration & dosage* / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D007505:Iron-Dextran Complex / Q000627:therapeutic use; D058185:Magnetite Nanoparticles / Q000627:therapeutic use; D008320:Maltose / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
D005290:Ferric Compounds; D058185:Magnetite Nanoparticles; C522335:ferric carboxymaltose; D008320:Maltose; D007505:Iron-Dextran Complex; D007501:Iron; D052203:Ferrosoferric Oxide